TP53 and prostate cancer: To this aim, we chose to use two cell lines characterized by high aggressive behavior and invasiveness: MDA, a breast cancer cell line that lacks of functional p53 due to a missense mutation [25] and PC3, a prostate cancer cell line with a mutation in the p53 gene that results in a truncated protein [26].